RE: This is a RTO not a Merger6 May 2020 18:21
", which we all know is a lung disease".
I'm positive on the prospects here but there's no sense in not being aware that -
1. The SARS family are viruses, not bacteria, so most antibiotics won't have any effect, unless incidental.
2. COVID affects the lungs but it is not only a lung disease, also affecting liver, kidneys, perhaps heart... and perhaps more. That's why no-one should regard this as just another variant of influenza.
Secondary infections by bacteria may be an important part of the disease progress, so there might be a role here AND the MOTIF FDA application for Iclaprim was for skin infections, not lung infections. One possibility is that someone sees value in reapplying to the FDA for lung therapeutics. Also bear in mind that the FDA is not the only authoriser of medicinal therapeutics ... other nations and groups of nations have their own procedures and priorities, so applying for a lung therapeutic may have some value there also.